#China #Nanjing #Roche #Simcere Zaiming #Antibodies

Simcere Zaiming and Roche: A Strategic Licensing Agreement for SIM0660's Global Development

On September 1, 2026, Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group, announced a landmark exclusive global licensing agreement with Roche. This collaboration aims to push forward the development and commercialization of SIM0660, a promising tri-specific antibody that targets CD79a, CD19, and CD3. This innovative approach holds incredible therapeutic potential, particularly for diseases mediated by B-cells.

Under the licensing terms, Roche gains exclusive rights to develop, manufacture, and commercialize SIM0660. Additionally, Simcere Zaiming stands to benefit significantly from this partnership, with potential payments reaching up to $1.53 billion, inclusive of a $75 million upfront payment. Furthermore, the company is entitled to tiered royalties based on future net sales, signaling a lucrative profit-sharing agreement.

The Science Behind SIM0660

SIM0660 has been developed utilizing Simcere Zaiming's proprietary technology known as T-cell engager poly-specific antibody technology. This revolutionary molecule combines an engaging arm for CD3 with binding domains targeting B-cell antigens, namely CD79a and CD19. This combination is designed to induce a strong T cell-mediated cytotoxic response, while simultaneously limiting harmful cytokine release.

The dual-targeting nature of SIM0660 makes it particularly promising for treating a broad spectrum of B-cell mediated diseases. It may prove beneficial for patients who have previously undergone treatment with CD20- or CD19-directed therapies. Moreover, its potential extends to B-cell-mediated autoimmune diseases, where it can assist in targeted depletion of pathogenic B cells, potentially providing significant clinical benefit.

Joint Commitment to Innovation

Renhong Tang, Chairman and CEO of Simcere Zaiming, expressed enthusiasm about the partnership, emphasizing the company's commitment to develop ground-breaking T-cell engagers through their TCE platform. Tang stated, “We are pleased to collaborate with Roche to accelerate the clinical development of SIM0660. Through our synergistic innovation, we hope to benefit global patients soon.”

Roche's Corporate Business Development Head, Boris L. Zaïtra, reported the company’s dedication to partnering with innovative firms to enhance therapeutic options for patients. He commented, “This agreement with Simcere Zaiming reflects our commitment to advancing and delivering new therapeutic options for patients in need. SIM0660 represents a potential advancement for patients with B-cell-mediated diseases.”

A Track Record of Successful Collaborations

This collaboration marks the latest in a series of successful out-licensing transactions for Simcere Pharmaceutical Group, with a total consideration exceeding $6.1 billion. As a company centered on oncology, Simcere Zaiming is focused on addressing the unmet clinical needs of cancer patients worldwide. Their impressive research and development pipeline boasts unique clinical assets, and the company has already successfully launched numerous innovative therapies in China, including products like Enzeshu, COSELA, and Endostar.

Conclusion

As Simcere Zaiming collaborates with Roche, both companies are poised to make strides in the treatment landscape for patients suffering from B-cell mediated diseases. By leveraging their unique technologies and expertise, they aspire to create new, effective therapeutic options that could transform patient care. The partnership symbolizes a strategic alignment of shared goals, driven by a common vision to offer advanced treatments to those in need across the globe.